# Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer

> **NCT07745296** · PHASE3 · NOT_YET_RECRUITING · sponsor: **UNICANCER** · enrollment: 990 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** Futibatinib
- **DRUG:** Ivosidenib + Capecitabine
- **DRUG:** Zanidatamab + Capecitabine
- **DRUG:** Capecitabine (Xeloda)

## Key facts

- **NCT ID:** NCT07745296
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-02
- **Primary completion:** 2033-07-02
- **Final completion:** 2033-07-02
- **Target enrollment:** 990 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07745296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07745296, "Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07745296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*